Invizius

Edinburgh, United Kingdom Founded: 2018 • Age: 8 yrs
Priming solutions for hemodialyzers are developed to reduce blood reactions.
Annual revenue - Latest available
Total funding $13.1M 6 rounds
Employees 12 Tracked headcount
Investors 10 Known backers
Products 2 Services tracked
Competitors 10 Brand Intelligence

About Invizius

Invizius is a company based in Edinburgh (United Kingdom) founded in 2018. Invizius has raised $13.09 million across 6 funding rounds from investors including Mercia, Downing and Scottish Enterprise. The company has 12 employees as of December 31, 2021. Invizius offers products and services including H-Guard and PspCN. Invizius operates in a competitive market with competitors including VenoStent, Renal Solutions, Redsense Medical, Health Line International Corporation and Peace and Quiet Care, among others.

  • Headquarter Edinburgh, United Kingdom
  • Employees 12 as on 31 Dec, 2021
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Invizius Limited
  • Date of Incorporation 26 Jan, 2018
  • Jurisdiction EDINBURGH, UNITED KINGDOM
Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $13.09 M (USD)

    in 6 rounds

  • Latest Funding Round
    $1.27 M (USD), Series A

    Sep 23, 2024

  • Investors
    Mercia

    & 9 more

  • Employee Count
    12

    as on Dec 31, 2021

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Invizius

Invizius offers a comprehensive portfolio of products and services, including H-Guard and PspCN.

Product name locked
Category locked
Primary

Complement therapy for patients on dialysis and extracorporeal circuits.

Product name locked
Category locked
Locked

Technology to supercharge natural regulators for enhanced efficacy.

Funding Insights of Invizius

Invizius has successfully raised a total of $13.09M across 6 strategic funding rounds. The most recent funding activity was a Series A round of $1.27 million completed in September 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Invizius

Invizius has secured backing from 10 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Mercia, Downing and Scottish Enterprise.

All
Venture Fund
Institutional
Angel
Investor Description Founded Year Domain Location
UK venture capital investments are managed by Calculus Capital.
Locked Locked Locked
-
Locked Locked Locked
Inheritance tax relief, funds, and bonds are provided across sectors.
Locked Locked Locked
Premium access

Investor details for Invizius

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Invizius

Investments
Premium access

Investment portfolio details for Invizius

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Invizius

Premium access

Detailed financials for Invizius

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Invizius Comparisons

Invizius Primary company
Description
Priming solutions for hemodialyzers are developed to reduce ...
Location
Edinburgh, United Kingdom
Founded Year
2018
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
12
As of 2021
Premium access

Peer comparison for Invizius

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Invizius

Invizius operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as VenoStent, Renal Solutions, Redsense Medical, Health Line International Corporation and Peace and Quiet Care, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Shape memory polymer stents are developed for vascular surgery applications.
Locked Locked Locked
Sorbents for renal replacement therapy are developed using regenerative technology.
Locked Locked Locked
Blood access is monitored during hemodialysis via alarm systems.
Locked Locked Locked
Contract Manufacturer of Dialysis products, Also sells own product lines.
Locked Locked Locked
Develops innovative renal dialysis machines with soundproof boxes.
Premium access

Detailed competitors of Invizius

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Invizius

Premium access

Complete news archive for Invizius

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Invizius

Invizius was founded in 2018.

Invizius is headquartered in Edinburgh, United Kingdom. It is registered at Edinburgh, Scotland, United Kingdom.

Richard Boyd is the current CEO of Invizius.

Invizius is a funded company, having raised a total of $13.09M across 6 funding rounds to date.

As of Dec 31, 2021, the latest employee count at Invizius is 12.

Invizius was founded in 2018 in Edinburgh, United Kingdom, within the medical devices sector focused on dialysis technology. Priming solutions for hemodialyzers are developed by the company, with H-Guard as the primary product under development. This solution incorporates a hemocompatible coating to mitigate foreign body reactions in blood during dialysis procedures. Applications target hollow fibers in dialyzers, where membrane inflammation in patients blood is addressed through reduced interactions.

Invizius's top competitors include VenoStent, Redsense Medical and Renal Solutions.

Invizius offers H-Guard and PspCN.

Invizius has 10 investors. Key investors include Mercia, Downing, Scottish Enterprise, Calculus Capital, and Solvay.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available